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Tuberculosis (TB) treatment is long and complex, typically involving a combination of drugs taken for 
6 months. Improved drug regimens to shorten and simplify treatment are urgently required, however 
a major challenge to TB drug development is the lack of predictive pre-clinical tools. To address this 
deficiency, we have adopted a new high-content imaging-based approach capable of defining the 
killing kinetics of first line anti-TB drugs against intracellular Mycobacterium tuberculosis (Mtb) residing 
inside macrophages. Through use of this pharmacokinetic-pharmacodynamic (PK-PD) approach we 
demonstrate that the killing dynamics of the intracellular Mtb sub-population is critical to predicting 
clinical TB treatment duration. Integrated modelling of intracellular Mtb killing alongside conventional 
extracellular Mtb killing data, generates the biphasic responses typical of those described clinically. Our 
model supports the hypothesis that the use of higher doses of rifampicin (35 mg/kg) will significantly 
reduce treatment duration. Our described PK-PD approach offers a much needed decision making 
tool for the identification and prioritisation of new therapies which have the potential to reduce TB 
treatment duration.
Tuberculosis (TB) is a highly infectious disease, with one third of the world’s population being latently infected 
and accounting for an estimated 1.5 million deaths in 20141. It is widely acknowledged that in the era of the 
Sustainable Development Goals, continued reduction in TB-related deaths will require improved tools for TB 
control, among them more effective drug regimens capable of shortening and simplifying treatment of the dis-
ease from months to weeks, and drugs that are effective against multi drug resistant (MDR) and extensively drug 
resistant (XDR) strains which can make the disease untreatable. A major challenge to TB drug development is 
the lack of validated predictive in vitro and in vivo pre-clinical tools that can be used to identify potential new 
drug candidates or drug combinations/regimens that confidently translate to shorter treatments in the clinic2, 3. 
In the case of moxifloxacin (MOX) for example, efficacy data acquired using current in vitro and in vivo models 
predicted the potential for a shortened treatment regimen4–6. Unfortunately, these pre-clinical model end points 
did not translate to humans and in a recent clinical trial in which MOX replaced either ethambutol (EMB) or 
isoniazid (INH), MOX did not shorten the standard 6 month TB treatment to 4 months7. One conclusion from 
this costly and time-consuming exercise is that we currently do not have validated pre-clinical discovery strategies 
capable of confidently supporting decision-making.
Typically, clinical studies report a biphasic response in the bacillary load to treatment with short-course 
regimens (e.g. ref. 8). A long-standing explanation for this phenomenon, is that the target population of 
Mycobacterium tuberculosis (Mtb) in patients is heterogeneous in terms of its response to different components 
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of therapy9. Generally, it is accepted that in order to understand the overall pattern of the clinical response, 
there is the need to understand the pharmacodynamic (PD) contribution to bacterial killing i.e. how different 
sub-populations of Mtb respond to specific drug treatment (e.g. refs 10–12), and pharmacokinetic (PK) contribu-
tion to killing dynamics i.e. the ability of a drug to reach Mtb sub-populations residing in different cells, matrices 
and tissues (e.g. refs 10, 13, 14).
Critically, the PK and/or PD characteristics of a drug(s) that are most relevant in predicting the clinical 
response of an anti-tubercular drug/drug combinations remain to be defined and validated. Currently, several 
pre-clinical animal and in vitro efficacy models are being evaluated to determine their value in forecasting clinical 
outcomes2, 3.
It has long been recognized that intracellular Mtb growth and survival within macrophages plays a major role 
in TB pathogenesis15. Intracellular survival necessitates metabolic and physiological adaptations relative to extra-
cellular growth. Significantly, Mtb that are genetically manipulated to lack genes required for survival within mac-
rophages fail to establish pathogenicity in TB animal models16–19. Consequently, it is clear that demonstration of 
efficacy against intracellular Mtb must be a critical PD feature for any anti-tubercular drug under development20.
The importance of determining the PD response of intracellular Mtb is underscored by studies that demon-
strate differential susceptibility to existing and novel anti-tubercular drugs and inhibitors against intracellular 
versus extracellular Mtb (e.g. refs 21–23). However, to date, studies assessing intracellular Mtb sensitivity to drugs 
do not allow for extrapolation and prediction of the clinical potential of the developing therapy. To address this 
deficiency, here we describe a new high-content imaging-based, PK-PD approach that utilizes concentration and 
time-dependent phenotypic data of intracellular Mtb residing within macrophages exposed to first-line TB drugs. 
We demonstrate that the use of intracellular Mtb-derived PD data, alongside conventional extracellular Mtb PD 
data, results in the generation of superior clinical predictions of TB treatment duration with biphasic responses 
akin to those described previously in the clinic. In addition, we show that our model can be used to simulate new 
therapeutic regimens such as the use of higher doses of RIF (35 mg/kg) to predict the outcomes of clinical studies. 
We anticipate that our described high-content imaging platform and PK-PD approach will be an invaluable tool 
that can correctly identify new combination therapies that can genuinely reduce TB treatment duration in the 
clinic.
Results
Growth rate of Mtb within macrophages is significantly reduced compared to planktonic Mtb 
grown in liquid culture. The described optimized high-content imaging platform permitted spatial meas-
urement of H37Rv-GFP Mtb residing within macrophages (Fig. 1). Longitudinal data of intracellular H37Rv-
GFP Mtb growth over 5 days were analyzed using an exponential, capacity saturated model (see Methods) and 
the growth rate was calculated as 0.033 h−1 (doubling time 21 h, Table 1 and Supplementary Fig. 1). These data 
Figure 1. Automated work flow of image analysis in Harmony. THP-1 macrophages infected with GFP-H37Rv 
were imaged on the Operetta platform described in the Methods section. The images were subsequently 
analysed with Harmony software in the following work flow (a) Image capture from one field of view displaying 
brightfield (grey), Hoechst (blue), and GFP-H37Rv (green). (b) Image without brightfield, displaying Hoechst 
(blue) and GFP-H37Rv (green). (c) Identification of extracellular GFP-H37Rv, detected M. tuberculosis are 
highlighted in red, the nucleus of the macrophages is in grey. (d) Identification of the nucleus of macrophages, 
detected nuclei (pink). (e) Cytoplasm detection, cytoplasm in blue and yellow. (f) M. tuberculosis infected 
macrophage (outline in orange), intracellular M. tuberculosis highlighted in red.
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are delineated from Mtb growing in liquid culture, (doubling time determined to be approximately 9 h) based 
on colony count data generated in house (Supplementary Fig. 1 and ref. 24) which agrees with data reported 
elsewhere25.
Intracellular Mtb residing within macrophages are killed more slowly by first line drugs. The 
optimized high-content imaging platform was used to measure the pharmacodynamic response of intracellular 
Mtb within macrophages to first line TB drugs at concentrations spanning the pharmacological range over an 
exposure period up to 120 h. Optimal assay performance was assessed and confirmed by a mean Z′-factor of 0.67 
for the complete data set.
RIF, INH, ETB and PZA exhibited time- and concentration-dependent anti-tubercular activity against intra-
cellular Mtb (Fig. 2). The kill dynamics for each drug was modelled as described in eq. 2 and the resultant kinetic 
parameters Emax (Maximum kill rate of a drug) and EC50 (concentration required to achieve half of this maximal 
kill rate) are presented in Table 1. In terms of intracellular Mtb killing dynamics, RIF ranked as the most effective 
out of all four drugs exhibiting an Emax value of 0.055 h−1 and an EC50 value of 18.4 ng/mL, followed by ETB, PZA 
and then INH. The raw (Fig. 2) and simulated (Supplementary Fig. 2) time- and concentration-dependent intra-
cellular Mtb killing kinetics revealed that maximal killing was achieved for all drugs after an initial lag period of 
20–48 h.
Comparison of intracellular and extracellular killing dynamics for all drugs show that intracellular Mtb resid-
ing inside macrophages exhibited much slower Emax values compared to kill rates shown previously in liquid 
cultures24, 25 and parameterised in Table 1.
To facilitate the comparison, concentration-kill rate relationship plots were performed for each drug (Fig. 3). 
A comparison of the concentration-intracellular kill rate relationship for all 4 drugs reveals the superiority 
of RIF over the other drugs, displaying the highest achievable Emax and a low EC50 (Fig. 3a). Plots comparing 
concentration-kill rate relationships for extracellular25 versus intracellular Mtb, show that despite broadly com-
parable EC50 levels, RIF, ETB and INH all display accelerated kill rates in the liquid assay compared to kill rates 
for intracellular Mtb (Fig. 3b–d).
PK-PD modelling using macrophage intracellular Mtb kill rates is predictive of treatment dura-
tion. To determine whether the PD data acquired from the intracellular macrophage high content platform 
has value in forecasting clinical TB treatment scenarios, Monte-Carlo PK-PD simulations for RIF, ETB, INH and 
PZA were conducted based on 1,000 theoretical subjects. Using published clinical PK parameters26–31, simula-
tions were performed for different treatment regimens using either intracellular or extracellular Mtb PD data, or 
a combination of both.
A simulation of the recommended WHO treatment regimen of an intensive 8 week treatment phase of RIF, 
ETB, INH and PZA followed by a 16 week continuation phase of RIF, INH using PD parameters taken from 
extracellular (liquid culture) Mtb data, reveal that median clearance time to achieve a 107 Mtb/ml log drop would 
take 16 days (Fig. 4a). This predicted rapid clearance contrasts with the simulations using intracellular Mtb PD 
parameters (Table 1 and Fig. 3) which predict a median clearance time of 56 days to achieve the same reduction 
of Mtb as predicted based on liquid culture (Fig. 4b). Significantly, simulations that combine both extracellular 
and intracellular Mtb PD parameters, result in a biphasic response for Mtb clearance, the intersection of which 
is dependent on the starting proportions of the two populations (Fig. 4c). The majority of Mtb in advanced 
disease states are found to be extracellular32, 33. Simulations of a standard 6 month treatment as per WHO rec-
ommendations, assuming that 95% of Mtb is extracellular and the rest 5% intracellular, results in 83% of patients 
achieving cure whilst the 17% remaining would be predicted to fail treatment (Fig. 4d). Notably, it is the killing 
dynamics of the intracellular Mtb population that predominantly determine the treatment duration. Sensitivity 
analysis across a wide range of intracellular:extracellular ratio fractions (1%:99%–99%:1%) results in minimal 
Treatment Parameter
Macrophage 
(intracellular 
Mtb)
Liquid* 
(extracellular 
Mtb)
Control Kgmax (h
−1) 
(D.Time) 0.033 (21.0 h)
0.0769–0.045 
(9.0 h)
Rifampicin
Emax (h−1) 0.055 0.178
EC50 (ng/mL) 18.4 5.60
Ethambutol
Emax (h−1) 0.053 0.142
EC50 (ng/mL) 79.5 264
Isoniazid
Emax (h−1) 0.041 0.710, 0.055
EC50 (ng/mL) 32.1 790
Pyrazinamide
Emax (h−1) 0.043 NA
EC50 (ng/mL) 45.5 NA
Table 1. Comparison of growth and pharmacodynamic killing kinetics for planktonic (extracellular liquid 
culture) and intracellular (macrophage) M. tuberculosis. Kgmax represents the maximal growth rate, Emax 
represents the maximal possible kill rate and EC50 the concentration required to achieve 50% of the Emax rate of 
kill. Parameters were derived from data generated from multiple independent experiments (n ≥ 3) performed in 
triplicate. NA, Not applicable. *For comparison, extracellular PD parameters based on in house and published 
values24, 25.
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variation (<8%) in total population achieving cure at the end of standard therapy whilst variation in median time 
to achieve cure changes by no more than 13 days (22%) regardless of assumed initial intracellular/extracellular 
ratio at the beginning of the simulation (Supplementary Fig. 3). We conducted a further comparison of our 
simulated standard 6 month treatment with clinical data obtained from the control arm of a recent Phase 3 trial 
(REMoxTB7). Kaplan-Meier estimates showing the time until conversion to culture-negative status, show that 
our simulations using growth and kill curves from 95:5% extracellular: intracellular Mtb-based PK-PD modelling 
compare very favourably with the clinical scenario (Fig. 4e).
Using our models, it is possible to make predictions of the clinical outcomes of proposed trials using the drugs 
we have investigated such as proposed high dose rifampicin34, 35. Simulations using high dose RIF (35 mg/kg) 
exposures again show a biphasic response due to differential killing dynamics of extracellular and intracellular 
Mtb (Fig. 4f). Significantly, assuming a 95:5%, extracellular:intracellular ratio of Mtb, simulations predict that 
only 12 weeks (~3 months) of a high dose RIF-containing treatment should deliver a clinical outcome equivalent 
to a 6 month HRZE standard course (87% cure and 13% failure rate, Fig. 4f). A predicted reduced time until 
conversion to culture-negative status for high dose RIF compared to standard treatment is further illustrated in 
Kaplan-Meier simulations (Fig. 4e).
Figure 2. Intracellular (macrophage) M. tuberculosis time-dependent kill. Panels display time-kill profiles of 
RIF (a), ETB (b), INH (c), and PZA (d). Data is mean ± S.D derived from multiple independent experiments 
(n ≥ 3) performed in triplicate.
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Discussion
Survival of Mtb within macrophages is a critical aspect of TB pathogenicity15. TB drug discovery efforts that 
have failed to simulate physiological growth conditions have resulted in the identification of false positive hits 
in drug screening and discovery programmes that have translated poorly to in vivo models (and man) and that 
are therefore not developable3, 36. The intracellular macrophage environment offers the ability to measure Mtb 
drug dynamics within an environment that better reflects the common niche of this pathogen. Reflecting the 
nutritionally-constrained environment of the intracellular macrophage milieu37, the population growth of intra-
cellular Mtb residing within macrophages was much slower (~21 h doubling time, Table 1 and Supplementary 
Fig. 1) compared with Mtb grown in stirred liquid culture which has a doubling time of approximately 9 h24, 25 
(Table 1 and Supplementary Fig. 1).
Drug susceptibility of Mtb residing within macrophages has previously been shown to correlate poorly with 
that of extracellular Mtb. This has been explained by invoking selective inhibition of pathways essential for intra-
cellular metabolism21, 23 or poor permeability/altered drug transport38 into these intracellular compartments. 
Our imaging data, measuring the intracellular Mtb response to first-line TB drugs, clearly demonstrates altered 
drug dynamics compared to extracellular Mtb (Table 1, Figs 2 and 3). Most notably, the maximum rate of Mtb 
elimination (Emax) that is achievable for RIF, ETB and INH is dramatically reduced compared to extracellularly 
grown Mtb (Table 1, Figs 2 and 3). Significantly, the inability to increase the Emax using super-pharmacological 
concentrations of drug, suggests that this phenomenon is not solely linked to intracellular drug availability 
which has been linked to altered RIF susceptibility when measured using static assays38. Instead, we hypothesise 
that the kill rate (Emax) of RIF, INH and ETB (a comparison of PZA cannot be made using the standard liquid 
culture conditions used here) is intimately linked to the inherent growth rate of the intracellular Mtb residing 
within the nutritionally-constrained environment of the macrophage (the same logic would apply to Mtb in 
any intracellular/compartmental niche that constrains growth dynamics). A link between growth-rate and kill 
rate for antibiotics that target the replication machinery of the cell has been described for many years (e.g. refs 
Figure 3. Intracellular (macrophage) and extracellular M. tuberculosis time-kill relationships. (a) Simulated 
concentration–kill rate relationship based on parameters generated from analysing intracellular Mtb kill curves 
for RIF (black circles), ETB (black triangles), INH (black diamonds) and PZA (black squares). (b) shows the 
concentration–kill relationship for RIF intracellular (black circles) and extracellular (open circles). (c) show the 
concentration–kill relationship of ETB intracellularly (black triangles) and extracellularly (open triangles) and (d) for 
the concentration–kill relationship of INH intracellularly (black diamonds) and extracellularly (open diamonds).
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Figure 4. PK-PD Monte-Carlo simulations of clinical Mtb response based on concentration-kill rate 
dynamics derived from in vitro models of intracellular and extracellular Mtb. (a) Predicted dynamics of total 
TB in patients receiving HRZE combination for 6 months based on extracellular kill rates only. (b) Predicted 
dynamics of total TB in patients receiving HRZE combination for 6 months based on intracellular kill rates 
only. (c) Predicted dynamics of total TB in patients receiving HRZE combination for 6 months based on the 
assumption that extracellular TB constitutes 95% and intracellular 5% of total TB (1-month view). (d) Predicted 
dynamics of total TB in patients receiving HRZE combination for 6 months based on the assumption that 
extracellular TB constitutes 95% and intracellular 5% of total TB (6-month view). (e) Probability of sputum 
sample conversion to Mtb culture-positive status over time as observed in TB patients receiving standard HRZE 
treatment in a previous clinical study7 (solid black line) compared to the predicted probabilities over time 
using our novel PK-PD model (dashed red line). Dashed green line shows our PK-PD prediction when using 
a standard HRZE regimen but with an elevated dose of RIF (35 mg/kg). The comparison assumes that the limit 
of detection for positive culture conversion is 10 CFU/mL when using Löwenstein–Jensen medium culture 
assays67 which have been implemented in the comparator clinical study. (f) Predicted dynamics of total TB in 
patients receiving HRZE with a high dose of RIF (35 mg/kg) for 3 months on the assumption that extracellular 
TB constitutes 95% and intracellular 5% of total TB (6-month view).
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39–41). The mechanisms underpinning growth-rate dependent killing of some antibiotics are beginning to be 
understood. Antibiotics targeting the ribosome for example, growth-rate-dependent killing is explained by the 
growth rate-dependent partitioning of the cell’s translational resources between production of new ribosomes 
and production of other proteins40, 42, 43. Single-cell studies have also recently confirmed that phenotypic anti-
biotic tolerance, often described as persistence, can be demonstrated in actively growing bacteria44, including 
Mycobacterium species45 and is not therefore wholly dependent on rare stochastic non-dividing (also known as 
dormant) populations46.
The significance of reduced kill rate (Emax) values for RIF, INH and ETB in intracellular Mtb experiments 
relative to kill rate (Emax) values derived from liquid culture experiments of extracellular Mtb, is that PK-PD pre-
dictions of clinical scenarios can be radically skewed from clinical reality. This is illustrated in the PK-PD simula-
tions performed using extracellular (Fig. 4a) and intracellular (Fig. 4b) Mtb drug dynamic parameters, resulting 
in dramatically different times to culture conversion. The majority of Mtb in advance disease state are found to 
be extracellular32, 33, assuming a ratio of 95% extracellular to 5% intracellular Mtb following treatment results in 
biphasic TB elimination profiles (Fig. 4c) that are similar to the treatment responses reported clinically following 
short-course regimens47, 48. It is noteworthy that treatment response in terms of both duration and cure (%) dis-
played only minimal variation in sensitivity analyses performed across a wide range of intracellular:extracellular 
ratio fractions (1%:99%–99%:1%, Supplementary Fig. 3).
Simulations of a standard 6 month treatment as per WHO recommendations, assuming that 95% of TB is 
extracellular and the rest 5% intracellular, results in 83% of patients achieving cure whilst the 17% remaining 
would be predicted to fail treatment (Fig. 4d). This agrees with literature data relating to relapse rates after stand-
ard 6 month TB treatment49. Simulations of standard WHO treatment duration lasting 2 months are predicted 
to result in a 50% cure rate, this is again in agreement with clinical studies50, 51. Moreover, the simulations are 
consistent with clinical observations showing a predominant role for INH during the initial fast Mtb elimination 
phase (INH was measured to have the fastest Emax for extracellular Mtb, Table 1) whilst RIF has the predominant 
role during the second slower elimination phase (RIF was measured to have the fastest Emax for intracellular Mtb, 
Table 1)52.
The described high-content imaging platform makes possible the dynamic measurement of intracellular Mtb 
in response to any drug. By linking the intracellular kill kinetics with drug exposure, and in this regard we under-
line the importance of acquiring accurate drug measurements in relevant compartments/tissues (e.g. ref. 13), it 
is possible to simulate clinical scenarios that can be validated against actual trial data. Here, we described this 
approach for high dose RIF trials (35 mg/kg) which are currently under clinical evaluation (e.g. refs 34, 35). 
Strikingly, simulations using PD data from intracellular Mtb exposed to high RIF concentrations (Fig. 2a) predict 
that clinical outcome equivalent to a 6 month HRZE standard course (83% cure and 17% failure rate, Fig. 4e) 
would occur within a significantly shorter time period (12 weeks) of a high dose RIF-containing treatment, 
reducing treatment therefore by approximately a half of the usual length. Our simulations are consistent with 
clinical data from Phase II studies in which rate increases in the dose of RIF result in an accelerate rate of decline 
in bacterial load34, 53–56.
Mtb within macrophages play a critical role in the life history of TB infection. The dynamic drug response of 
intracellular Mtb residing inside macrophages is dramatically different to that of extracellular Mtb. In essence, for 
drugs affecting the replication machinery, maximum kill kinetics are intimately linked with compartmentalized 
growth dynamics. The critical importance of this observation is that the dynamic intracellular Mtb drug response 
(compared to extracellular killing) provides the most predictive estimates of clinical treatment response. The 
described dynamic high-content imaging platform offers a new tool to aid decision-making and is recommended 
for incorporation as an essential assay for compound progression within the TCP (target candidate profiles) of 
future TB drug discovery programmes aiming to identify therapies that reduce treatment duration.
Methods
Chemical Compounds. The compounds Isonicotinic Acid Hydrazide (Isoniazid, INH), Rifampicin (RIF), 
Ethambutol Dihydrochloride (ETB), Pyrazinoic Acid Amide (Pyrazinamide, PZA) were purchased from Sigma. 
All compounds, except Pyrazinamide, which was made up in media, were made up in DMSO (Sigma). Final 
DMSO concentration was adjusted and used at 0.1% in all test conditions.
Mycobacterial Strains and Mtb Growth. Mtb H37Rv expressing a green fluorescent protein 
(H37Rv-GFP) was used in this study. The recombinant H37Rv-GFP contains an integrative plasmid (pENVY1) 
carrying the Green Fluorescent Protein (gfp) gene constitutively expressed from a HSP60 promoter (a kind gift 
from Professor T. Parish). H37Rv-GFP was pre-cultured aerobically at 37 °C in Middlebrook 7H9 broth (Difco) 
supplemented with 0.05% (v/v) Tween 80 (Sigma), 0.2% (v/v) glycerol, 10% oleic acid-albumin-dextrose-catalase 
(OADC) (hereafter called 7H9) and 50 µg/ml hygromycin (Sigma) for 14 days.
Extracellular Mtb time-kill studies. Mid-log phase Mtb H37Rv was diluted to 1 × 107 CFU/mL in 7H9. 
Aliquots of 1.5 mL of bacterial culture with magnetic stirrers was incubated aerobically at 37 °C in the presence 
or absence of drug. At three time points per day for up to 7 days, optical density (600 nm) was measured (begin-
ning from day 0). In experiments in which colony forming units (CFUs) were measured, aliquots of culture were 
withdrawn at periodic intervals and pelleted material washed in drug-free Middlebrook 7H9 media before CFU/
mL determination by colony counting on solid growth media containing Middlebrook 7H11 agar plates supple-
mented with 10% oleic acid–albumin–dextrose–catalase solution (Becton Dickinson), 0.2% (v/v) glycerol and 
0.05% (v/v) Tween 80.
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Macrophage Infection Assay in 96-Well Plates, High-content Image Acquisition and 
Analysis. THP-1 cells were routinely cultured in RPMI 1640 with L-Glutamine and NaHCO3 (Gibco) sup-
plemented with 10% heat-inactivated foetal bovine serum (FBS; Gibco), at 37 °C, 5% CO2. For the infection assay 
THP-1 cells were differentiated in 96-well Matriplate plates (MGB096-1-2-LG-L Black 0.17 low glass; Brooks). 
THP-1 cells were seeded at 5 × 105 cells per well and differentiated for 72 h in RPMI 1640 with L-Glutamine and 
NaHCO3 supplemented with 10% heat-inactivated FBS and 100 ng/ml phorbol 12-myristate 13-acetate (PMA; 
Sigma) at 37 °C, 5% CO2. The medium was removed after 72 h and THP-1 cells incubated for a further 24 h in 
RPMI 1640 with L-Glutamine and NaHCO3 supplemented with 10% FBS at 37 °C, 5% CO2. Differentiated THP-1 
cells were infected with H37Rv-GFP in suspension at a multiplicity of infection (MOI) of 1:5 in RPMI 1640 with 
L-Glutamine and NaHCO3 supplemented with 10% heat-inactivated FBS for 24 h at 37 °C. After 24 h the cells 
were washed and the drugs at the required concentrations added. Infected cells were incubated for up to 5 days 
at 37 °C, 5% CO2. At each time point, plates were fixed with 5% paraformaldehyde (PFA) (Sigma) for 2 h before 
staining. Macrophages were stained with Hoechst 3442 (Invitrogen) at 2 µg/mL in PBS for 30 min at 37 °C. Image 
acquisition was performed with an Operetta (PerkinElmer) using a 60x High NA objective. H37Rv-GFP were 
detected using 460/490 nm excitation coupled with a 500/550 nm detection filter and Hoechst 3442 labeled cells 
were detected using excitation at 360/400 nm laser coupled with a 410/480 nm detection filter. Fourteen fields and 
a Z stack of 6 intervals over 0–6 µm were recorded for each plate well. Each image was processed using Harmony 
3.5.1 analysis software (PerkinElmer). Briefly, the cell nucleus was segmented using detection of Hoechst 3442. 
From this the cell area was defined again using Hoechst 3442 (due to cellular RNA staining). Within each mac-
rophage the spot finding algorithm was utilised to detect the area of H37Rv-GFP in each cell. The output param-
eter deduced from the images was the bacterial load, which refers to the total surface area of all the green objects 
that reside within the macrophages, as a ratio of total cell area. Data were generated from multiple independent 
experiments (n ≥ 3) performed in triplicate. Assay performance was measured using Z′-factor determination57.
Pharmacodynamic data analysis. The growth dynamics of Mtb were calculated according to an exponen-
tial, capacity saturated model which takes into account the saturation of growth that was observed at day 5 with 
control experiments. The growth rate was calculated according to Eq. 1 taken from58:
= ⋅ ⋅



−



dMtb
dt
Mtb Kg Mtb
POPMAX
1
(1)max
where Mtb represents the total Mtb count in the well at any given time (t), Kgmax represents the maximal growth 
rate per unit time and POPMAX represents the maximum capacity of the Mtb population in a well, in other 
words the maximum limit of Mtb number per well.
A model that calculates the kill dynamics of drugs over multiple time points was developed based on previous 
work58, in contrast to calculating fixed time point MIC or IC50 values. The kill dynamics for each drug in the assay 
were modelled simultaneously over 5 days with all the tested concentrations (a gradient of 12 concentrations per 
drug ranging from 0.5 ng/mL to 32 µg/mL). We use the term ‘kill rate’ to describe the rate of reduction of Mtb 
growth per unit time, e.g. when the kill rate is equal to the growth rate, the number of Mtb will remain constant 
and when the kill rate exceeds the growth rate, the number of Mtb will decline over time, and vice versa. The 
model calculates the most likely values of Emax (Maximum possible kill rate of a drug per unit time) and C50 (con-
centration required to achieve half of this maximal kill rate) based on all the available data from all the tested drug 
concentrations according to Eq. 2:
= ⋅ ⋅



−


 − ⋅
⋅ .
+ .
dMtb
dt
Mtb Kg Mtb
POPMAX
Mtb E conc
C conc
1
(2)max
max
50
Using Eq. 2 the model calculates the maximal kill rate of each drug per unit time as well as the C50 value that 
is required to achieve half of that rate.
For extracellular Mtb growth and kill dynamics, we used a combination of in-house data of Mtb grown (plank-
tonic) in liquid media as well as previously published kill dynamic data of first-line drugs published by our labora-
tory24 and that of other groups e.g. ref. 25 using the same model to allow for intracellular-extracellular dynamics 
comparisons.
Monte-Carlo Simulations. The growth and kill parameters estimated from the intracellular and extracel-
lular assays were used to predict the PK-PD relationship in a clinical context. The PK parameters of all four drugs 
were taken from the literature26, 27, 30, 31, 59–66. The PK-PD model linked the PK to the PD component by using the 
simulated dynamic drug concentrations in a patient to represent ‘conc’. In Eq. 2. When combining multiple drugs 
it was assumed that the rate of kill is equal to that of the drug that achieves the higher kill rate based on its concen-
tration and kill rate (based on the argument that you can only kill once and there is no underlying synergy/antag-
onism between the drugs). This was achieved by using IF statements in the Pmetrics model file that are applied 
at each time step. The simulation was then run assuming that all four drugs are administered concomitantly once 
daily for a period of 8 weeks followed by RIF and INH for a further period of 18 weeks, as per standard WHO 
treatment recommendations. The simulation is aimed at identifying the time it takes to achieve a 7 log reduction 
of Mtb, as such a drop is correlated with a cure in clinical studies48. Variability was set at 30% for the PK parame-
ters whilst the variability and limits of the PD parameters were set according to the modelling of the in-vitro data.
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